The experimental setup was deliberately grounded in real-world conditions. Juvenile pompano, averaging about nine grams, were acclimated at 29 degrees Celsius before being randomly assigned to control tanks or heat-stress tanks, where the water was warmed by one degree per hour until it reached 34 degrees and held there for a week. That figure is not arbitrary: summer waters in southern China’s aquaculture regions now approach 34 degrees regularly, well above the species’ optimal growth range of roughly 22 to 28 degrees. Every fish in both groups survived the full seven days, but the heat-exposed animals drifted apart from their schooling cohesion and swam less spontaneously — early behavioral hints that something deeper was wrong.

Under the microscope, the damage was unmistakable. Control livers showed the tidy architecture expected of healthy teleost tissue: hepatocytes arranged in orderly cords around a central vein, sinusoids clear and well-formed. In the heat-stressed group, that order collapsed. Hepatocytes loosened and lost their distinct boundaries, cytoplasm filled with vacuoles, nuclei shrank, shifted position, or dissolved entirely, sinusoids ballooned outward, and inflammatory cells infiltrated the tissue. The authors interpret this as a significant sublethal challenge — hot enough to disrupt hepatic homeostasis, not yet hot enough to kill. That distinction matters, because it captures precisely the conditions commercial farms face each summer: fish that live, but at a physiological cost.

At the biochemical level, the heat triggered a full mobilization of antioxidant defenses. The Nrf2 pathway — the master switch for cellular redox protection — lit up, with elevated expression of Nrf2 itself along with its downstream targets heme oxygenase-1 and NQO1, and even its own regulator Keap1. Total antioxidant capacity and anti-superoxide activity rose in parallel. Perhaps counterintuitively, the classic markers of oxidative damage — lipid peroxidation products and malondialdehyde — actually fell, along with hydrogen peroxide. The team reads this not as an absence of stress but as an effective compensatory response: the antioxidant machinery ramped up fast enough to scavenge reactive oxygen species before they could shred membrane lipids. Yet the simultaneous drop in glutathione, glutathione peroxidase activity, and anti-hydroxyl radical capacity reveals that the system was running a deficit even while winning battles — redox homeostasis remained partially disrupted.

One of the study’s most technically interesting threads involves ferroptosis, the iron-dependent form of cell death driven by lipid peroxide accumulation. Heat exposure raised hepatic iron levels and increased expression of NCOA4, the gene that drives ferritin degradation and releases stored iron into the cell — a move that, on its own, would raise ferroptotic vulnerability. But the fish counterprogrammed. Ferritin heavy chain 1 and ferroportin 1, which sequester and export iron respectively, were upregulated alongside NFS1, which builds iron-sulfur clusters. The GPx4-mediated lipid peroxide detoxification axis strengthened too, with GPx4, the cystine transporter SLC7A11, and p53 all rising together. Although PTGS2, a canonical ferroptosis marker, was elevated, the actual lipid peroxidation products declined. The verdict: ferroptosis-related regulation was visibly rearranged, but the execution of ferroptosis itself was not evident — adaptation, not self-destruction.

The immune picture was less reassuring. Pro-inflammatory signaling surged, with interleukin-1β and tumor necrosis factor-α both upregulated. But the anti-inflammatory arm did not respond in a coordinated way: TGF-β rose while interleukin-10 fell, a divergent pattern the authors describe as dysregulated anti-inflammatory control. More worrying for farmers, IL-8 — which recruits immune cells to inflammatory sites — was downregulated, and so were the immunoglobulin genes IgM and IgT, the workhorses of systemic and mucosal antibody immunity in fish. In plain terms, the liver was inflamed but poorly defended: alarm bells ringing while the security guards were sent home. This aligns with field observations that heat-stressed pompano become more susceptible to bacterial and parasitic infections, and it offers a mechanistic explanation for why summer disease outbreaks track water temperature.

Apoptosis-related genes showed a similarly split profile. CHOP, the transcriptional sentinel of endoplasmic reticulum stress, was upregulated along with the executioner caspases 9 and 3, while cytochrome C expression fell. The pattern suggests heat pushed cells toward the apoptotic cascade transcriptionally, even as the mitochondrial release pathway behaved unexpectedly. The authors are careful here — these are coordinated transcriptional responses affecting apoptotic homeostasis, not proof of widespread cell death, and the divergence between genes hints that different apoptotic routes respond to thermal stress on different timetables.

The most novel contribution lies in bile acids. Using liquid chromatography–tandem mass spectrometry, the team quantified 14 of 39 targeted bile acid species and found that heat stress selectively shrank the pool of unconjugated, free bile acids, with cholic acid, chenodeoxycholic acid, and 7-ketolithocholic acid dropping significantly — three metabolites the authors flag as potential biomarkers of thermal stress. Meanwhile the genes governing bile acid handling responded in kind: FXR, the nuclear receptor that orchestrates bile acid homeostasis, rose alongside SULT1 and UGT8, enzymes that detoxify and eliminate hydrophobic bile acids. Because excess hydrophobic free bile acids can damage membranes and fuel oxidative injury, the researchers interpret the shrinkage as adaptive — a way of limiting bile acid cytotoxicity under heat. Intriguingly, FXR activation is known in other systems to suppress lipid peroxidation and ferroptosis, and here its upregulation coincided with rising GPx4 and falling lipid peroxide markers, suggesting bile acid remodeling and antioxidant defense may be two faces of the same stress program.

The study has limits the authors acknowledge candidly: sample sizes were adequate but modest, feeding and growth were not quantitatively tracked, and standard liver injury markers such as ALT and direct hepatic ROS measurements were not taken. Even so, the work lands at a practical moment. As marine heatwaves intensify in the South China Sea, heat stress is becoming a structural constraint on pompano farming rather than an occasional bad summer. By showing exactly which molecular levers a heat-stressed liver pulls — Nrf2-driven antioxidant mobilization, iron recalibration without ferroptosis, immune suppression, and a deliberate contraction of the free bile acid pool — the study points toward targeted interventions, most immediately bile acid-based functional feed additives that could support the FXR axis before temperatures climb. For a species now central to China’s mariculture output, that is the difference between watching livers quietly reorganize under heat and actually helping them do it.

Subject of Research: Hepatic physiological and bile acid metabolic responses of Trachinotus ovatus to high-temperature stress

Article Title: High-temperature stress response in the liver of Trachinotus ovatus: a cascade of oxidative stress, immunity, and bile acid metabolic reprogramming

Article References: Zhu, R., Xiao, M., Huang, X., Zhang, D., Zhou, F., Yang, Y., Guo, H., & Duan, Y. (2026). High-temperature stress response in the liver of Trachinotus ovatus: a cascade of oxidative stress, immunity, and bile acid metabolic reprogramming. Stress Biology, 6(1), Article 71. https://doi.org/10.1007/s44154-026-00344-y

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00344-y

Keywords: Trachinotus ovatus, heat stress, aquaculture, liver, oxidative stress, bile acids, ferroptosis, Nrf2, immune suppression, FXR, marine heatwaves, metabolomics

The research, led by Wenling Ye, Yang Zhao, and Fengling Wang under the direction of corresponding authors Wei-Dong Chen and Yan-Dong Wang, focused on the farnesoid X receptor, or FXR, a ligand-activated transcription factor expressed abundantly in the liver and intestine. FXR has long been recognized as a master regulator of bile acid homeostasis, lipid metabolism, and glucose control, and several FXR agonists have already entered clinical development for cholestatic liver disease and non-alcoholic steatohepatitis. The new work adds an unexpected dimension to this receptor’s portfolio: it appears to govern how the liver rebuilds its resident population of macrophages, the Kupffer cells, after surgical injury.

Kupffer cells are the liver’s resident sentinels, embedded in the sinusoidal blood vessels that perfuse the organ. They clear circulating debris and pathogens, but during regeneration they do something equally important: they broadcast the inflammatory and growth-promoting signals that push hepatocytes out of their quiescent state and into the cell cycle. Because these cells are consumed and reprogrammed as regeneration proceeds, the liver must continuously replenish its Kupffer cell pool from two sources. The first is local, the proliferation of resident Kupffer cells that survived the initial insult. The second is systemic, the recruitment of monocytes circulating in the bloodstream, which home to the injured liver and differentiate into macrophage-like cells that can take up residence there.

To test whether FXR controls this replenishment program, the team used a mouse model of two-thirds partial hepatectomy, the standard experimental system for studying liver regeneration. In wild-type mice, the regenerating lobes showed robust activation of both T cells and Kupffer cells, with increased infiltration of these immune populations into the remnant tissue, exactly the kind of coordinated immune response that regeneration theory predicts. The picture in mice lacking FXR was strikingly different. Although these animals started with elevated baseline numbers of both T cells and Kupffer cells in their livers, once surgery removed two-thirds of the organ, their regenerating livers displayed markedly attenuated immune activation and reduced immune cell infiltration compared with normal mice.

The consequence was a measurable delay in regeneration. The researchers traced this defect to failures in both arms of the Kupffer cell replenishment pathway. In FXR-deficient mice, circulating monocytes were less able to migrate into the regenerating liver, starving the organ of fresh macrophage precursors. At the same time, the resident Kupffer cells that remained proliferated poorly, so the local self-renewal route was also compromised. With both supply lines disrupted, the Kupffer cell pool failed to recover its normal size and composition, and the polarization balance between classically activated M1 macrophages and alternatively activated M2 macrophages was altered, further disturbing the cytokine environment that regenerating hepatocytes require.

Mechanistically, the study identified two molecular pathways through which FXR exerts this control. The first operates on monocyte trafficking. FXR, acting as a transcription factor, directly targets the gene encoding CCR2, the chemokine receptor that serves as the homing beacon for inflammatory monocytes. CCR2 allows circulating monocytes to sense chemokines released by injured tissue and migrate along the gradient toward the wound. By promoting CCR2 expression, FXR effectively keeps the recruitment pipeline open during regeneration. When FXR is absent, this beacon dims, monocytes fail to arrive in sufficient numbers, and the liver loses its most important source of replacement macrophages.

The second pathway governs local proliferation. The researchers found that FXR enhances the expansion of resident Kupffer cells through the CSF1/PI3K/Akt signaling cascade. Colony-stimulating factor 1, or CSF1, is the essential survival and growth factor for cells of the mononuclear phagocyte lineage, and signaling through its receptor activates phosphoinositide 3-kinase and the Akt kinase, a canonical pathway that drives cell growth, survival, and division. By potentiating this cascade in Kupffer cells, FXR ensures that the resident population can double and repopulate the regenerating tissue. The two mechanisms work synergistically: one replenishes the pool from the blood, the other from within, and together they restore Kupffer cell homeostasis at the pace that regeneration demands.

The study also offers a possible explanation for a clinical observation that has long frustrated transplant surgeons and hepatologists: regenerative capacity declines with age. In aged mice, the researchers observed impaired monocyte recruitment to the regenerating liver, mirroring the defect seen in FXR-deficient animals. If the same age-related erosion of the FXR-monocyte axis occurs in humans, it could help explain why elderly patients recover more slowly from major hepatic resection and why organs from older donors regenerate less vigorously after transplantation. This finding reframes aging of the liver not simply as a decline in hepatocyte proliferative potential but as a failure of the immune support system that scaffolds that proliferation.

The clinical implications are considerable. Liver transplantation and partial hepatectomy remain the most effective therapies for end-stage liver disease, yet the persistent shortage of donor organs has intensified interest in interventions that could enhance regeneration, expand the pool of usable grafts, and improve post-surgical outcomes. The identification of the FXR-Kupffer cell axis as a central regulator of liver repair suggests a concrete therapeutic target. Small-molecule FXR agonists, several of which are already approved or in late-stage clinical trials for other liver conditions, could in principle be repurposed or optimized to boost monocyte recruitment and Kupffer cell expansion in patients undergoing hepatic resection or receiving partial grafts from living donors.

As with any mouse study, important questions remain before these findings can be translated. The work was conducted in genetically engineered mice lacking FXR entirely, and the timing, dose, and cell-type specificity of any future pharmacological intervention will need careful optimization. It will also be essential to determine whether activating FXR in humans produces the same immune cell effects without exacerbating the inflammatory components of chronic liver disease, since macrophage polarization is a double-edged sword in conditions such as fibrosis and cirrhosis. Nevertheless, by connecting a well-characterized metabolic receptor to the cellular logistics of immune replenishment, the study adds a compelling new layer to the biology of liver regeneration. It suggests that the liver’s famous ability to rebuild itself rests not only on the proliferative drive of its hepatocytes but on a receptor-controlled program that recruits, renews, and reactivates the macrophages those hepatocytes depend on, and that keeping this program running may one day mean the difference between a graft that thrives and one that fails.

Subject of Research: FXR regulation of Kupffer cell pool restoration during liver regeneration

Article Title: An FXR-dependent cellular program for Kupffer cell pool restoration fuels liver regeneration

Article References: Ye, W., Zhao, Y., Wang, F., Wang, Y., Qu, Y., Li, Y., Wang, Y.-D., & Chen, W.-D. (2026). An FXR-dependent cellular program for Kupffer cell pool restoration fuels liver regeneration. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03398-z

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03398-z

Keywords: liver regeneration, FXR, Kupffer cells, monocyte recruitment, CCR2, CSF1, PI3K/Akt signaling, partial hepatectomy, macrophage polarization, liver transplantation, aging, nuclear receptor

Ferroptosis is fundamentally a lipid chemistry problem. Unlike apoptosis, which proceeds through genetically scripted signaling cascades, ferroptosis occurs when iron-catalyzed chemical reactions, akin to Fenton chemistry, attack the polyunsaturated fatty acids within membrane phospholipids and convert them into destructive lipid hydroperoxides. Phosphatidylethanolamines carrying two polyunsaturated fatty acyl tails are particularly dangerous substrates, because their bis-allylic hydrogen atoms are easily abstracted by free radicals, initiating peroxidation chain reactions that rupture the membrane and kill the cell. The cell’s principal defense is the enzyme glutathione peroxidase 4, or GPX4, which reduces these phospholipid hydroperoxides back to harmless lipid alcohols, while a parallel suppressor, ferroptosis suppressor protein 1, or FSP1, quenches lipid radicals independently of glutathione. The balance between the production of oxidizable polyunsaturated phospholipids and their repair defines a cell’s ferroptotic sensitivity.

The central proposal of the new review is that in cholangiocarcinoma this balance may be governed by a specific molecular ratio: the abundance of membrane phosphatidylethanolamines containing monounsaturated fatty acids relative to those containing polyunsaturated fatty acids. The authors term this proposed dynamic equilibrium the ferroptotic rheostat. Monounsaturated fatty acids lack the vulnerable bis-allylic positions that make their polyunsaturated cousins susceptible to peroxidation, so when they are incorporated into membrane phospholipids they dilute the pool of oxidizable substrates and render the membrane chemically resistant to ferroptotic execution. The review argues, as an explicit working hypothesis rather than an established mechanism, that the position of this MUFA-PE to PUFA-PE ratio may be a principal determinant of ferroptotic fate in bile duct cancer cells.

The most direct evidence for this idea in cholangiocarcinoma comes from a single untargeted lipidomic study of four cholangiocarcinoma cell lines, published by Sae-Fung and colleagues in npj Precision Oncology in 2024. That work identified acyl-CoA synthetase long-chain family member 4, ACSL4, as the enzyme that channels polyunsaturated fatty acids into membrane phospholipids and thereby promotes ferroptosis sensitivity, while its isoform ACSL3 preferentially activates monounsaturated fatty acids such as oleate for incorporation into membranes. In the cholangiocarcinoma cell lines examined, ACSL3-driven enrichment of monounsaturated phosphatidylethanolamines conferred resistance to ferroptosis, and ACSL3 expression emerged as an unfavorable prognostic marker in patient cohorts. The review is careful to flag that this remains the only CCA-specific, functionally integrated evidence for a membrane-lipid-based resistance mechanism, and that the critical ratio has never been measured directly in human cholangiocarcinoma tumor tissue.

Upstream of ACSL3, the review situates the rheostat within the broader machinery of de novo lipogenesis. The fatty acid synthase FASN manufactures the saturated fatty acid palmitate, which the enzyme stearoyl-CoA desaturase 1, SCD1, then desaturates into monounsaturated species that can be deployed into membranes as ferroptosis-proofing material. ATP-citrate lyase, ACLY, supplies the acetyl-CoA substrate that feeds this entire lipogenic pipeline by cleaving citrate exported from the mitochondrion. Each of these enzymes has been implicated in cholangiocarcinoma progression through transcriptomic and functional studies: FASN-mediated fatty acid biosynthesis remodels the immune environment of parasite-associated intrahepatic cholangiocarcinoma, a circular RNA called MBOAT2 promotes tumor progression by stabilizing the messenger RNA of FASN, ACLY shows pathological significance and prognostic value in patient samples, and pharmacological degradation of acetyl-CoA carboxylase 1 attenuates lipid accumulation and tumor growth. The review stresses, however, that apart from the ACSL3-MUFA axis, the individual links connecting these lipogenic enzymes to ferroptosis resistance in cholangiocarcinoma rest largely on bioinformatic inference or evidence imported from other tumor types rather than on direct redox lipidomic measurement in human bile duct cancer tissue.

What distinguishes cholangiocarcinoma from most other cancers is its intimate exposure to bile, and the review devotes particular attention to a crosstalk axis that is essentially unique to this tumor’s microenvironment. Bile acids, the detergent-like molecules that cholangiocytes bathe in daily, activate the farnesoid X receptor, FXR, a nuclear receptor that regulates lipid homeostasis. Work in hepatocyte models has shown that FXR activation by bile acids suppresses lipid peroxidation and protects cells from ferroptosis, raising the tantalizing possibility that the bile acid-rich environment of the biliary tree continuously pushes the ferroptotic rheostat toward resistance in cholangiocarcinoma cells. The authors are explicit that this prediction, derived from hepatocyte studies, has not yet been tested in cholangiocarcinoma itself, and they flag it as a hypothesis in need of direct experimental validation. Given that cholestasis and altered bile acid composition are hallmark features of the biliary diseases that predispose patients to cholangiocarcinoma, this axis represents one of the most distinctive and clinically relevant frontiers of the proposed model.

The review also identifies a genetically defined entry point for ferroptosis sensitization in a subset of patients. Roughly fifteen to twenty percent of intrahepatic cholangiocarcinomas carry mutations in the metabolic enzymes isocitrate dehydrogenase 1 or 2, IDH1 and IDH2. These mutations cause the enzymes to produce the oncometabolite 2-hydroxyglutarate, which competitively inhibits alpha-ketoglutarate-dependent dioxygenases and drives epigenetic dysregulation. Crucially for ferroptosis biology, the mutant enzymes also consume NADPH, the reducing equivalent that cells need to regenerate their antioxidant defenses, including the CoQ10 pool maintained by FSP1. Studies in cell models have shown that 2-hydroxyglutarate production by mutant IDH1 sensitizes cells to ferroptosis through this NADPH depletion, and circulating 2-hydroxyglutarate is already being explored as a biomarker in IDH-mutant cholangiocarcinoma patients. This suggests that a molecularly defined subgroup of bile duct cancers may be intrinsically more vulnerable to ferroptosis-inducing therapies, an idea that could be exploited with existing IDH inhibitors or ferroptosis-inducing compounds.

Beyond the lipogenic and bile acid axes, the review surveys a crowded landscape of ferroptosis regulators implicated in cholangiocarcinoma by recent functional studies. The cystine transporter SLC7A11, which imports the amino acid needed for glutathione synthesis, is upregulated by the Golgi phosphoprotein GOLPH3 and by the m6A methyltransferase METTL16, both of which suppress ferroptosis and promote malignancy. The tumor suppressor p53 and its metabolic effector TP53-induced glycolysis and apoptosis regulator influence ferroptotic resistance in intrahepatic tumors, while large-scale functional genomic screens have revealed differential dependence on GPX4 between intrahepatic and extrahepatic cholangiocarcinoma. Iron metabolism itself is dysregulated in cholangiocarcinoma stem-like cells, and the ferritinophagy receptor NCOA4, which liberates iron from ferritin stores, has emerged as a potential therapeutic target. Each of these findings adds a layer to the regulatory network that ultimately converges on the same endpoint: the oxidation state of the membrane phospholipid pool.

Perhaps the most valuable contribution of the review is its unflinching honesty about the state of the evidence. The authors state at the outset that the ferroptotic rheostat is a proposed model, not an established mechanism, and they systematically flag which links in the framework are supported by direct measurement and which rest on transcriptomic correlation or cross-tumor extrapolation. They conclude by outlining the priority research gaps that must be closed before any lipid-centric intervention strategy could be considered in patients. Foremost among these is the systematic application of redox phospholipidomics, using liquid chromatography coupled to high-resolution mass spectrometry to quantify oxidized phospholipid species directly, and spatial lipidomics, which maps lipid distributions within intact tissue sections, to human cholangiocarcinoma biospecimens. Only such measurements, the authors argue, can test, refute, or refine the model. If validated, the rheostat concept would reframe ferroptosis from a binary switch into a tunable parameter, opening a rational path toward combination therapies that first strip the monounsaturated armor from cancer cell membranes with SCD1 or FASN inhibitors, and then trigger the peroxidative collapse that the sensitized membrane can no longer withstand.

Subject of Research: The role of membrane lipid composition, particularly the MUFA-PE to PUFA-PE ratio, in regulating ferroptosis sensitivity in cholangiocarcinoma

Article Title: Lipidome as a ferroptotic rheostat in cholangiocarcinoma: A proposed model and its current evidence base

Article References: Köse-Demirtaş, B., & Kurtoğlu, D. (2026). Lipidome as a ferroptotic rheostat in cholangiocarcinoma: A proposed model and its current evidence base. Molecular Biology Reports, 53(1), Article 1636. https://doi.org/10.1007/s11033-026-12819-2

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12819-2

Keywords: cholangiocarcinoma, ferroptosis, lipidomics, lipid peroxidation, ACSL3, SCD1, FASN, bile acids, FXR, IDH1/2 mutations, phospholipids, metabolic reprogramming

FXR, the farnesoid X receptor, is expressed predominantly in the liver, intestine, and kidneys, and functions as the body’s principal bile acid sensor. Its endogenous ligands are bile acids themselves, with binding potency following a clear hierarchy: chenodeoxycholic acid is the strongest activator, followed by deoxycholic acid, lithocholic acid, and finally cholic acid. Once activated, FXR operates a sophisticated transcriptional network that keeps bile acid levels in check. In the liver, it ramps up production of the small heterodimer partner, a transcriptional repressor that shuts down CYP7A1 and CYP8B1, the two enzymes that drive bile acid synthesis. In the intestine, FXR triggers the release of fibroblast growth factor 15 in rodents and 19 in humans, which travels through the portal vein to the liver and binds the FGFR4 receptor complex to suppress bile acid production through a second, independent route. The review emphasizes that this dual feedback system is most powerful in the liver, with weaker but meaningful effects in the small intestine and kidneys.

Beyond bile acid chemistry, FXR acts as a metabolic conductor. Activation of the receptor suppresses SREBP-1c, the master switch for fatty acid and triglyceride synthesis, through SHP-dependent signaling, while simultaneously boosting PPARα activity to upregulate carnitine palmitoyl transferase 1 and accelerate fat burning through beta-oxidation. FXR also reshapes the fatty acid profile of the liver, lowering both monounsaturated and polyunsaturated fatty acid levels through distinct mechanisms. Its influence extends to glucose: protein kinase A-mediated phosphorylation of FXR activates gluconeogenic gene expression, while intestinal FXR stimulates secretion of glucagon-like peptide-1, the incretin hormone made famous by blockbuster diabetes and obesity drugs, thereby promoting insulin release and improving glucose tolerance. The receptor additionally damps inflammation by suppressing NF-κB signaling, reducing interleukin-6 and interleukin-1β, and by directly blocking the assembly of the NLRP3 inflammasome through SHP, preventing caspase-1 activation and the pyroptotic cell death that fuels hepatic inflammation.

The clinical implications of these mechanisms are enormous. In cholestatic liver diseases such as primary biliary cholangitis and primary sclerosing cholangitis, where toxic bile acids accumulate and destroy tissue, FXR agonists have been the leading therapeutic strategy for years. Obeticholic acid, a derivative of chenodeoxycholic acid, became the first approved FXR agonist for primary biliary cholangitis in 2016 and showed promise in metabolic dysfunction-associated steatohepatitis as well. Yet the review delivers a striking update: amid persistent safety concerns and disappointing results in the COBALT trial, the manufacturer voluntarily withdrew obeticholic acid from the United States market in September 2025. Hepatotoxicity, severe pruritus, and unfavorable lipid changes had outweighed its benefits. The withdrawal casts a long shadow over the field and underscores why newer agents such as cilofexor, tropifexor, and vonafexor—each designed for better selectivity and tolerability—remain in various stages of clinical development, some already halted for lack of efficacy and others still advancing.

In fatty liver disease, the review describes FXR as a reliable intervention point operating through multiple converging pathways. The receptor inhibits fat production via the FXR-SHP-SREBP1c axis, promotes fat oxidation through PPARα, and induces detoxification enzymes such as CYP3A4 and sulfotransferase 2A1 to enhance bile acid clearance. Intriguingly, FXR also participates in a reciprocal positive feedback loop with SIRT1, the longevity-associated histone deacetylase: FXR induces SHP, which suppresses microRNA-34a and thereby lifts the brake on SIRT1 expression, while SIRT1 in turn deacetylates FXR, stabilizing it and promoting its nuclear translocation. Intestinal FXR adds another layer of protection by maintaining epithelial tight junctions, preserving the gut vascular barrier through Wnt/beta-catenin signaling, and upregulating antimicrobial defenses. In liver cancer, the evidence is equally compelling. Mice lacking FXR spontaneously develop hepatocellular carcinoma with bile acid accumulation and elevated beta-catenin target genes, and FXR activation directly disrupts the beta-catenin-TCF4 transcriptional complex while also suppressing tumor progression through the JAK2-STAT3 pathway and the FGF15/19-FGFR4 axis.

TGR5, the review’s second protagonist, tells a complementary story through entirely different cell biology. Rather than sitting in the nucleus, TGR5 is embedded in the plasma membrane, where bile acid binding triggers cyclic AMP production within seconds. It is distributed widely across the liver, gallbladder, intestine, kidney, spleen, brain, skeletal muscle, and brown adipose tissue, with ligand potency ranking lithocholic acid highest, followed by deoxycholic acid, chenodeoxycholic acid, and cholic acid. In metabolic terms, TGR5 activation promotes GLP-1 secretion from intestinal endocrine cells, enhances insulin sensitivity, and induces the browning of white adipose tissue. The review details two thermogenic mechanisms: cAMP-PKA signaling enhances the conversion of thyroid hormone T4 to the active T3, upregulating uncoupling protein 1 and driving mitochondrial heat production, while a parallel pathway induces mitochondrial creatine kinase 2 to establish a UCP1-independent futile creatine cycle. Together these actions increase energy expenditure and counteract obesity.

TGR5 also functions as an immunological brake. Its activation inhibits NF-κB and NLRP3 inflammasome signaling through the cAMP-PKA axis, steering macrophages away from the pro-inflammatory M1 phenotype and toward the reparative M2 state. In models of cholestasis induced by bile duct ligation, TGR5 knockout worsened oxidative stress and Kupffer cell polarization, while TGR5 agonists reduced damage by inhibiting NF-κB and activating the Nrf2/HO-1 pathway. In cancer, TGR5-deficient mice proved more susceptible to chemically induced liver cancer, and receptor activation suppressed tumor development through STAT3 inhibition. Agonist development, however, remains early: the semi-synthetic bile acid analog INT-777 has never entered human trials, while the next-generation candidate RDX8940 shows potent activity against insulin resistance and hepatic steatosis in preclinical models but still lacks human safety data. Antagonists such as SBI-115 and SBI-364, meanwhile, have revealed unexpected value in polycystic kidney and liver disease, where excessive TGR5 signaling drives aberrant bile duct proliferation.

Perhaps the review’s most important contribution is its portrait of FXR and TGR5 as an interlocking system rather than two isolated targets. The two receptors coordinate bile acid homeostasis, with FXR providing the slow transcriptional feedback and TGR5 handling rapid metabolic responses. Along the gut-liver axis, bile acids activate FXR in enterocytes to release FGF15/19 while simultaneously engaging TGR5 on intestinal L cells to secrete GLP-1, and gut microbes remodel bile acid structures into conjugates that can activate both receptors at once. During liver regeneration, knockout of either receptor delays recovery, indicating partial functional compensation that is not fully interchangeable. In the intestinal epithelium the two receptors actually pull in opposite directions—FXR restrains proliferation through cell-cycle inhibitors like p21 while TGR5 promotes it through cAMP-PKA and EGFR crosstalk—creating a delicate balance that maintains tissue homeostasis.

The review closes with a candid assessment of the obstacles ahead. Only a small fraction of FXR- and TGR5-targeted drugs have reached clinical use, and most candidates suffer from low bioavailability, short duration of action, or side effects such as pruritus, dyslipidemia, and hepatotoxicity. FXR biology is strikingly tissue-dependent: only about 11 percent of FXR binding sites are shared between mouse liver and intestine, and while single-organ knockout produces mild phenotypes, double knockout causes severe cholestatic injury, revealing that hepatic and intestinal FXR cannot substitute for one another. TGR5’s role in primary sclerosing cholangitis remains genuinely contested, with evidence both for cholangiocyte-protective and disease-promoting functions depending on context. The authors call for deeper mechanistic mapping of cell-type-specific receptor functions, next-generation dual-target modulators, combination strategies with GLP-1 receptor agonists, and rigorously designed trials. For a field still reeling from obeticholic acid’s withdrawal, the message is clear: bile acid receptors remain among the most promising targets in hepatology, but realizing that promise will require matching the elegance of the biology with equally sophisticated pharmacology.

Subject of Research: The roles of the bile acid receptors FXR and TGR5 in hepatic steatosis, fibrosis, cholestatic disease, and hepatocellular carcinoma

Article Title: The Bile Acid Signaling Axis: Deciphering the Roles of FXR and TGR5 in Hepatic Steatosis, Fibrosis, and Cancer

Article References: Liu, J., Sun, K., Liu, H., Zhu, M., Li, C., He, Y., & Qin, L. (2026). The Bile Acid Signaling Axis: Deciphering the Roles of FXR and TGR5 in Hepatic Steatosis, Fibrosis, and Cancer. Pharmacology Research & Perspectives, 14(5), Article e70318. https://doi.org/10.1002/prp2.70318

Image Credits: AI Generated

DOI: 10.1002/prp2.70318

Keywords: bile acids, FXR, TGR5, liver fibrosis, hepatocellular carcinoma, MASLD, MASH, cholestasis, obeticholic acid, GLP-1, NF-kB, gut-liver axis

Cholestasis arises when the delicate plumbing of the liver fails. Bile, a detergent-like fluid produced by hepatocytes to carry away cholesterol, toxins, and metabolic waste, must be exported through a series of specialized transporter proteins embedded in the canalicular membrane of liver cells. When that export system breaks down, bile acids back up inside hepatocytes, where their detergent properties become a weapon against the very cells that produce them. The result is oxidative stress, inflammatory signaling, programmed cell death, and eventually fibrosis. Among the transporters involved, the bile salt export pump, known as BSEP, occupies a central position. It is the primary efflux pump for conjugated bile acids, and its dysfunction is widely regarded as a key initiating event in cholestatic liver damage, whether the cause is a genetic mutation, a drug side effect, or a chemical insult.

To model this injury experimentally, the researchers turned to alpha-naphthyl isothiocyanate, or ANIT, a compound long used to induce intrahepatic cholestasis in laboratory animals. ANIT damages the biliary epithelium and disrupts canalicular transport, producing a cascade of biochemical and histological changes that closely mirror human cholestatic disease. Sixty male Sprague Dawley rats were randomly assigned to five experimental groups: a healthy control group, a group receiving ANIT alone, two groups pretreated with selenium at doses of 0.5 and 1 milligram per kilogram of body weight before ANIT exposure, and a group receiving selenium alone to assess the element’s intrinsic safety profile at these doses.

The damage inflicted by ANIT was comprehensive. The researchers documented marked suppression of BSEP, along with two other critical transporters, MRP2 and NTCP, which together coordinate the import and export of bile acids and their metabolites across hepatocyte membranes. Simultaneously, the expression of genes governing bile acid synthesis and detoxification, including CYP7A1, UGT1A1, and the nuclear receptor FXR that orchestrates much of bile acid homeostasis, was thrown into disarray. These molecular disruptions translated into measurable clinical harm: serum markers of cholestasis and liver injury climbed, oxidative stress intensified, inflammatory signaling pathways were activated, and hepatocytes underwent increased apoptosis. Under the microscope, liver tissue showed pronounced histopathological injury and early fibrotic changes, confirming that the model had faithfully reproduced the destructive arc of cholestatic disease.

Selenium pretreatment changed that picture dramatically, but only at the higher dose. At 1 milligram per kilogram, the element significantly attenuated ANIT-induced damage across nearly all biochemical, molecular, and histopathological endpoints examined. Bile acid transporter expression was preserved, the balance of bile acid synthesis and detoxification was rebalanced, and the downstream consequences of transporter failure, including oxidative damage, inflammation, and cell death, were substantially blunted. By contrast, the lower dose of 0.5 milligrams per kilogram produced only partial improvements, and for several key parameters, including serum ALT, AST, GGT, and bilirubin levels as well as oxidative and inflammatory markers, the differences relative to the ANIT-only group did not reach statistical significance. This dose-dependence is a critical finding, suggesting that selenium’s protective window in this context is narrower than a simple more-is-better assumption might imply.

Delving into the signaling mechanisms, the team found that the protective effect was accompanied by activation of the NRF2/HO-1 axis, one of the cell’s master antioxidant defense systems, and by stimulation of Sirt1, a nutrient-sensing deacetylase with well-established roles in cellular stress resistance and metabolic regulation. At the same time, selenium suppressed inflammatory signaling mediated by TLR4 and the transcription factor NF-κB, a pathway that ANIT exposure had strongly activated. Perhaps most intriguingly, the researchers observed reactivation of PI3K/AKT/mTOR-dependent pro-survival signaling, suggesting that selenium did not merely mop up reactive oxygen species but actively shifted hepatocytes from a death-oriented to a survival-oriented signaling state. Together, these pathways form a coherent mechanistic narrative in which selenium stabilizes the liver’s bile acid export machinery while simultaneously fortifying its defenses against the oxidative, inflammatory, and apoptotic fallout of cholestatic stress.

The study also incorporated complementary computational analyses that provided structural support for the biological findings. Molecular docking experiments indicated that ANIT forms stable interactions within the inhibitory binding pocket of BSEP, consistent with the idea that the chemical directly interferes with the pump’s function. This structural insight is significant because BSEP inhibition has become a major concern in pharmaceutical development; drug candidates that block the pump are frequently flagged for cholestatic risk, and regulatory agencies and the International Transporter Consortium have emphasized BSEP inhibition testing as a tool for predicting liver injury liability. By anchoring the ANIT model to a structurally plausible mechanism of BSEP interference, the study strengthens the relevance of the selenium protection data to broader questions of drug-induced cholestasis.

Selenium itself is a fascinating and double-edged nutrient. As an essential trace element, it is incorporated into selenoproteins, including the glutathione peroxidases and thioredoxin reductases that form the biochemical backbone of antioxidant defense. Prior research has documented protective effects of selenium against oxidative injury in the kidney, the nervous system, and the liver in various toxicological models, and recent work has linked dietary selenium to amelioration of fatty liver disease through the KEAP1/NRF2 pathway. Yet the element also has a well-defined toxic threshold. The European Food Safety Authority has established a tolerable upper intake level for selenium, and excess intake can itself produce oxidative stress and selenosis. The dose-dependence observed in the current study, in which half the effective dose failed to confer significant protection, underscores that selenium biology is not a simple linear relationship between intake and benefit.

The authors are careful to frame their findings as evidence for a prophylactic rather than a therapeutic role. In the experimental design, selenium was administered before ANIT exposure, meaning the element was present in liver tissue before the cholestatic insult began. This pretreatment strategy allowed selenium to prime antioxidant defenses and stabilize transporter expression ahead of injury, but it does not demonstrate that selenium could reverse established cholestasis. For patients already suffering from cholestatic liver disease, whether from biliary obstruction, drug toxicity, or autoimmune conditions, the study does not yet provide a basis for selenium as a treatment. What it does provide is a proof of principle that maintaining hepatic redox homeostasis and BSEP expression before an insult can dramatically reduce the severity of the resulting injury.

The implications extend in several directions. For clinicians and nutrition scientists, the work adds hepatobiliary protection to the growing list of selenium-dependent health benefits, while reinforcing the importance of adequate but not excessive selenium status. For toxicologists and drug developers, the detailed mapping of the BSEP-FXR-centered protective network offers a mechanistic template for evaluating candidate cholestasis-preventing compounds. And for basic researchers, the study highlights the intricate interplay between bile acid transport, redox signaling, inflammatory pathways, and cell survival machinery that determines whether a stressed liver recovers or spirals into fibrosis. As cholestatic liver diseases continue to impose a substantial clinical burden worldwide, the humble trace element that helps glutathione peroxidase neutralize peroxides may prove to be an unexpectedly powerful ally, provided the dose, the timing, and the therapeutic window are respected with the precision this new research demands.

Subject of Research: Selenium pretreatment and protection against ANIT-induced cholestatic liver injury via BSEP preservation and redox homeostasis

Article Title: Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis

Article References: Bolat, İ., Özdemir, S., Çomakli, S., Sağlam, Y. S., Tekin, S., Çinar, B., Bolat, M., Orhan, B., Sağsöz, M. E., & Okkay, U. (2026). Selenium pretreatment alleviates ANIT-induced cholestasis by preserving BSEP expression and hepatic redox homeostasis. Molecular Biology Reports, 53(1), Article 1658. https://doi.org/10.1007/s11033-026-12849-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12849-w

Keywords: selenium, cholestasis, BSEP, ANIT, liver injury, oxidative stress, FXR, NRF2, bile acid transporters, NF-kB, hepatoprotection, rats

A team led by Min Deng of the State Key Laboratory of Molecular Oncology at the Cancer Hospital of the Chinese Academy of Medical Sciences, working with Zhenkun Lou of the Mayo Clinic and Bin Chen of Anhui University, has identified a tumor-intrinsic checkpoint that operates specifically in human cancer cells and is essentially absent from the murine models on which most radioimmunotherapy research is built. The circuit centers on three proteins: the farnesoid X receptor, or FXR, a nuclear receptor best known for its role in bile acid metabolism; TRIM22, an E3 ubiquitin ligase of the tripartite motif family; and STAT1, the transcription factor that sits at the heart of interferon signaling. In human tumor cells, the researchers found, radiation inadvertently activates this axis, and the result is a molecular strangulation of the very interferon program that radiation is supposed to unleash.

The mechanistic story begins with protein stability. The team showed that ionizing radiation stabilizes FXR in human cancer cells through the action of ubiquitin-specific peptidase 7, or USP7, a deubiquitinating enzyme that removes the ubiquitin tags that would otherwise mark FXR for proteasomal destruction. Once stabilized, FXR translocates its transcriptional activity toward a specific target: the gene encoding TRIM22. TRIM22, in turn, selectively binds STAT1 and catalyzes the attachment of K48-linked polyubiquitin chains, the canonical signal for degradation by the 26S proteasome. With STAT1 levels falling, the downstream interferon-stimulated gene program, the battery of ISGs that coordinates antigen presentation, T-cell recruitment, and inflammatory amplification, is extinguished precisely when radiation has done its work and the immune system should be mobilizing.

What makes this discovery particularly striking is its species specificity. When the researchers compared human and murine cancer cells, they found that mouse tumor cells simply lack a TRIM22 family member capable of destabilizing STAT1 in this way. Radiation therefore produces robust, sustained STAT1-dependent interferon signaling in mouse tumors, while the same insult in human cells is blunted by the FXR-TRIM22 circuit. This single proteostatic difference offers a mechanistic explanation for one of the most persistent frustrations in translational radiation oncology: the repeated failure of dramatic preclinical abscopal effects to translate into consistent clinical benefit. Decades of combination trials pairing radiation with immune checkpoint inhibitors have been designed around mouse data that, it now appears, were structurally incapable of revealing this human brake.

The consequences of dismantling the brake were demonstrated through genetic and pharmacologic means. When the team disrupted FXR or TRIM22 in human cancer cells, STAT1 was preserved, type I interferon signaling was amplified, and the irradiated tumor cells became markedly better at activating CD8-positive T cells. These effects were tested in peripheral blood mononuclear cell-humanized mouse models, which carry functional human immune components and human tumor cells, providing a far more faithful platform than conventional murine systems. In these humanized settings, loss of the FXR-TRIM22 axis enhanced abscopal tumor control, meaning that untreated tumors at distant sites regressed as the systemic immune response gathered strength, a phenomenon that has long been the holy grail of radiation-immunology research.

The pharmacologic arm of the study is where the work acquires its most immediate clinical resonance. Ursodeoxycholic acid, or UDCA, is a bile acid that has been used clinically for decades, primarily to treat cholestatic liver diseases and primary biliary cholangitis, with a long and well-characterized safety record. Prior work, including studies in morbidly obese patients, had suggested that UDCA exerts antagonistic effects on FXR signaling. The team reasoned that a safe, approved drug capable of dampening FXR might suppress the radiation-induced TRIM22 response and thereby preserve STAT1. That is exactly what they observed: UDCA treatment suppressed radiation-induced TRIM22 expression in human tumor cells, restored STAT1 protein levels and interferon-stimulated gene signaling, and potentiated the antitumor effects of radiotherapy in humanized models.

Crucially, the benefits extended to combination therapy. When UDCA was paired with radiotherapy and an anti-PD-1 immune checkpoint antibody in humanized mice, the triple combination produced superior tumor control without overt toxicity. This is a significant point, because the tolerability profile of UDCA is exceptionally well understood from its long hepatology track record, and any strategy that could enhance radioimmunotherapy using an already-approved, orally available drug would face a far shorter path to clinical testing than a purpose-built inhibitor of a novel target. The authors also note that the ubiquitin-proteasome machinery involved, including the E3 ligase TRIM22, belongs to target classes increasingly considered druggable in modern oncology, offering additional avenues if dedicated FXR or TRIM22 inhibitors are developed.

The study also contributes to a broader rethinking of how radiation and immunity interact in human tumors. It has long been appreciated that type I interferon signaling is a double-edged sword in cancer, with chronic or dysregulated interferon sometimes promoting immune escape, but the acute interferon burst following DNA damage is widely regarded as essential for effective antitumor immunity. By showing that a human-specific proteostatic checkpoint throttles that burst at the level of STAT1 stability, the work reframes the problem of radiation resistance: the issue is not that human tumors fail to sense DNA damage through cGAS-STING, but that a downstream transcriptional regulator is actively degraded before it can broadcast the alarm. Intervening at the level of protein stability, rather than at pathway activation, may therefore be the more effective strategy in patients.

Caveats remain, as they always do at this stage of translation. The evidence for the FXR-TRIM22-STAT1 axis and the efficacy of UDCA comes from cell lines and humanized mouse models, not yet from clinical trials, and the precise dosing, timing, and patient selection needed to deploy UDCA alongside radiation and checkpoint blockade in humans remain to be established. The authors declare no competing interests, and the RNA-sequencing data underpinning the transcriptional analyses have been deposited in public repositories for independent scrutiny. Still, the conceptual payoff is immediate: a human-biased mechanism that has been hiding in plain sight, masked by the very mouse models used to study it, now has a name, a circuit diagram, and a candidate drug. If the findings hold in patients, a decades-old bile acid could become an unexpected partner for radiation in the fight against cancer.

Subject of Research: A human-biased FXR-TRIM22-STAT1 immune checkpoint that limits radiation-induced antitumor immunity and its pharmacologic modulation by ursodeoxycholic acid

Article Title: Ursodeoxycholic acid enhances cancer radioimmunotherapy by releasing a human-biased FXR-TRIM22-STAT1 immune brake

Article References: Li, X., Jiang, P., Yin, H., Huo, Z., Xu, X., Nowsheen, S., Aziz, K., Zheng, S., Sun, N., Chen, B., Lou, Z., & Deng, M. (2026). Ursodeoxycholic acid enhances cancer radioimmunotherapy by releasing a human-biased FXR-TRIM22-STAT1 immune brake. Cell Research. https://doi.org/10.1038/s41422-026-01293-x

Image Credits: AI Generated

DOI: 10.1038/s41422-026-01293-x

Keywords: radiotherapy, radioimmunotherapy, FXR, TRIM22, STAT1, ursodeoxycholic acid, type I interferon, cGAS-STING, abscopal effect, CD8 T cells, ubiquitination, cancer immunotherapy

Nuclear receptors are ligand-activated transcription factors that bind specific DNA sequences and switch target genes on or off in response to small molecules. Several members of this superfamily are central players in bile acid biology. The farnesoid X receptor, or FXR, is the canonical bile acid sensor, activated by chenodeoxycholic acid and related species, and it feeds back to suppress the enzyme CYP7A1, the rate-limiting step in classical bile acid synthesis, largely through induction of the repressive nuclear receptor SHP. The pregnane X receptor and the constitutive androstane receptor act as xenobiotic and bile acid sensors that induce detoxification and export pathways, protecting hepatocytes from bile acid overload. The liver X receptor links oxysterol sensing to bile acid synthesis via CYP7A1 induction, while the retinoid X receptor serves as a common dimerization partner for many of these receptors. Each of these receptors, however, does not act alone: their output depends on the coregulatory proteins they recruit to DNA.

This is where SMRT enters the picture. SMRT, short for silencing mediator of retinoid and thyroid hormone receptors and also known as NCOR2, is one of the two major corepressors of the nuclear receptor superfamily, the other being its paralog NCoR1. In the absence of activating ligand, many nuclear receptors bind SMRT, which in turn recruits large multiprotein complexes containing histone deacetylases such as HDAC3, along with transducin beta-like proteins and other chromatin-modifying enzymes. These complexes deacetylate histones and maintain local chromatin in a transcriptionally repressive state. When ligand binds, the receptor undergoes a conformational change, releases the corepressor, and recruits coactivators instead. This ligand-dependent corepressor exchange is the fundamental switch that converts receptor binding into transcriptional activation, and it means that the abundance, localization, and post-translational modification state of SMRT directly shapes how strongly and how quickly target genes respond to their ligands.

For bile acid homeostasis specifically, SMRT has been implicated in the regulation of nearly every major nuclear receptor pathway in the hepatocyte and the enterocyte. In the FXR pathway, corepressor exchange at FXR target promoters such as SHP, BSEP, and the intestinal FGF15/FGF19 locus determines the strength of the enterohepatic feedback signal that restrains CYP7A1 expression. In the CAR and PXR pathways, SMRT occupancy at promoters of detoxification genes such as CYP2B and CYP3A, and at bile acid exporters, governs the inducible defense against cholestatic injury. In the LXR pathway, corepressor association with LXR/RXR heterodimers at the CYP7A1 promoter influences the balance between bile acid synthesis and cholesterol efflux. The review emphasizes that these are not independent circuits but an integrated network in which SMRT acts as a shared rheostat, tuning gene expression across pathways in response to nutritional state, circadian cues, and inflammatory signals.

The physiological consequences of disrupting this corepressor function are substantial. Animal studies over the past two decades have shown that perturbing corepressor complexes, particularly the SMRT- and NCoR-associated HDAC3 complex, produces profound metabolic phenotypes. Liver-specific deletion of HDAC3 in mice leads to marked alterations in lipid and bile acid metabolism, reflecting the loss of repressive chromatin marks at metabolic gene promoters. Similarly, mice with impaired corepressor recruitment to specific nuclear receptors display altered bile acid pool sizes, changes in the hydrophobicity of the bile acid pool, and altered sensitivity to cholestatic liver injury. Because bile acids themselves are cytotoxic at high concentrations and pro-carcinogenic when they accumulate in the intestine, the fidelity of this corepressor-mediated feedback is a matter of liver and gut health, not merely transcriptional housekeeping.

The review also highlights the emerging role of SMRT in the enterohepatic circulation itself. Bile acids are secreted into bile, stored in the gallbladder, released into the duodenum after meals, reabsorbed in the terminal ileum, and returned to the liver through portal blood. At each step, nuclear receptors in enterocytes and hepatocytes sense the local bile acid concentration and adjust transporter expression accordingly. SMRT-dependent repression and derepression at these transporter genes, including ASBT in the ileum and NTCP and BSEP in the liver, helps set the flux rate of the entire circulation. Disruption of this tuning can shift the bile acid pool toward more hydrophobic species, which are stronger FXR agonists but also more damaging to membranes, thereby creating a feedback loop that links corepressor function to both signaling intensity and cytotoxic risk.

Beyond classical bile acid metabolism, the review connects SMRT-regulated nuclear receptor signaling to systemic metabolic disease. Bile acids activate FXR and the membrane receptor TGR5 to influence glucose homeostasis, insulin sensitivity, thermogenesis in brown adipose tissue, and energy expenditure. The bile acid pool is also a major determinant of gut microbiome composition, and the microbiome in turn modifies bile acids through deconjugation and dehydroxylation, generating secondary bile acids with distinct receptor specificities. Because SMRT shapes the expression of the enzymes and transporters that determine which bile acids circulate and in what amounts, corepressor function sits upstream of this entire host-microbe metabolic axis. The authors argue that this positions SMRT as a potential node at which diet, microbiome, and nuclear receptor pharmacology converge, with implications for nonalcoholic fatty liver disease, cholestasis, metabolic syndrome, and gastrointestinal cancers.

Therapeutically, the framework has clear implications. FXR agonists such as obeticholic acid are already approved for certain cholestatic conditions and are being evaluated for metabolic liver disease, while dual and selective modulators of FXR, TGR5 agonists, and CAR activators are in various stages of development. The review suggests that the efficacy of such ligands depends not only on receptor binding but on the corepressor and coactivator landscape of the target tissue. A ligand that promotes efficient corepressor release will produce a stronger transcriptional response than one that does not, and tissue-specific differences in SMRT abundance could explain variable drug responses between patients and between liver and intestine. This perspective points toward a second generation of nuclear receptor therapeutics designed with coregulator exchange in mind, and toward biomarkers based on coregulator occupancy that could predict which patients will benefit from bile acid-directed therapies.

The review closes by identifying open questions that will define the next phase of the field. These include mapping the genome-wide occupancy of SMRT at bile acid-related loci in a cell-type-specific manner, determining how post-translational modifications of SMRT such as phosphorylation, ubiquitination, and sumoylation respond to nutritional and inflammatory signals, and clarifying how SMRT and NCoR1 divide labor between hepatocytes, cholangiocytes, and intestinal epithelial cells. Single-cell and chromatin profiling technologies are expected to accelerate this work, as are degrader and PROTAC approaches that can selectively manipulate corepressor complexes. What is already clear, the authors contend, is that bile acid homeostasis cannot be understood as a simple ligand-receptor-feedback circuit. It is a coregulator-dependent system in which SMRT provides the repressive counterweight that gives nuclear receptor signaling its dynamic range, its tissue specificity, and its resilience against metabolic and toxicological stress.

Subject of Research: SMRT corepressor regulation of nuclear receptor signaling in bile acid homeostasis

Article Title: SMRT regulation of nuclear receptors orchestrates bile acid homeostasis

Article References: Kim, K., Fang, S., Hong, S.-H., Cho, H., Leblanc, M., Jacinto, S., Schnabl, B., Atkins, A. R., Yu, R. T., Liddle, C., Truitt, M. L., Fan, W., Lee, C. M., Downes, M., & Evans, R. M. (2026). SMRT regulation of nuclear receptors orchestrates bile acid homeostasis. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01823-y

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01823-y

Keywords: SMRT, NCOR2, nuclear receptors, bile acids, FXR, CYP7A1, cholestasis, HDAC3, liver metabolism, enterohepatic circulation, corepressors, metabolic disease

The article begins with the fundamentals of bile acid physiology. Roughly 95 percent of the bile acids secreted into the intestine are actively reabsorbed in the ileum and recycled back to the liver through the portal vein, a circuit known as the enterohepatic circulation. Primary bile acids, chiefly cholic acid and chenodeoxycholic acid, are synthesized from cholesterol in the liver through pathways driven by the enzymes CYP7A1 and CYP27A1. Once they reach the intestine, gut bacteria convert them by dehydroxylation into secondary bile acids such as deoxycholic acid and lithocholic acid. These microbial derivatives do not simply linger in the gut; they enter the systemic circulation and exert far-reaching effects on host metabolism, intestinal health and inflammatory tone.

The mechanistic heart of the commentary lies in the receptors through which bile acids act. The farnesoid X receptor, or FXR, is a nuclear receptor abundant in liver, intestine and kidney that functions as the body’s bile acid thermostat. When bile acid concentrations rise, FXR binds them and triggers a negative feedback loop that suppresses CYP7A1, curbing further synthesis and preventing toxic accumulation. But FXR’s portfolio extends well beyond metabolic housekeeping. The authors highlight evidence that FXR activation restrains tumor invasion by downregulating matrix metalloproteinases, enzymes that degrade the extracellular matrix, and by dampening pro-inflammatory signaling and cell-cycle progression. The FXR agonist obeticholic acid, already validated in a phase 3 trial for non-alcoholic steatohepatitis, is flagged as a candidate for cancer therapy, potentially in combination with conventional chemotherapy.

A second receptor, TGR5, operates through entirely different circuitry. As a G protein-coupled receptor expressed on immune cells, intestinal epithelial cells and adipose tissue, TGR5 mediates non-genomic, rapid signaling. Its activation raises intracellular cyclic AMP, promotes thermogenesis in brown fat, improves insulin sensitivity and, critically, can halt the runaway proliferation of cancer cells by interfering with cell-cycle progression. TGR5 also modulates macrophages and T cells within the tumor microenvironment, reducing the chronic inflammation that fuels tumor growth. Together, the authors contend, FXR and TGR5 represent a paired molecular handle for therapeutic intervention in bile acid signaling.

The commentary is equally candid about bile acids’ dark side. Secondary bile acids such as deoxycholic acid can be frankly carcinogenic at high concentrations, particularly when they persist in the intestine for extended periods. They induce the production of reactive oxygen species, generating oxidative stress that damages DNA, proteins and lipids and seeds the mutations from which cancers arise—a mechanism considered especially relevant to colorectal cancer. Deoxycholic acid can also activate the Wnt/beta-catenin pathway, driving proliferation while suppressing apoptosis, and both deoxycholic and lithocholic acid trigger the release of pro-inflammatory cytokines such as TNF-alpha and IL-6 through JAK/STAT and NF-kappaB signaling. Chronic inflammation of this kind is regarded as a major pathogenic mechanism in digestive tract cancers, including colorectal and esophageal malignancies.

Woven through the analysis is the bidirectional relationship between bile acids and the gut microbiome. Bile acids shape which microbes thrive: their amphipathic structure allows them to disrupt bacterial membranes, induce DNA damage and provoke oxidative stress in susceptible organisms, while bacteria that express bile acid-metabolizing enzymes gain a survival advantage. In turn, microbes chemically transform bile acids. Bacteria secreting bile salt hydrolases cleave the glycine or taurine groups from conjugated bile acids, converting them into free bile acids with altered solubility and biological activity. Recent work has even uncovered entirely novel microbial bile acid species, such as the succinylated bile acid 3-sucCA, which promotes the growth of the beneficial bacterium Akkermansia muciniphila by regulating its glucose-utilizing NagB enzyme. The authors note that much remains to be learned about how manipulating the bile acid pool reshapes host-microbe communication.

One of the most provocative threads in the commentary concerns taurine, the amino sulfonic acid conjugated to many bile acids. Long celebrated as an antioxidant that neutralizes reactive oxygen species, protects DNA integrity and restrains inflammation by inhibiting NF-kappaB and steering macrophages away from a pro-inflammatory M1 phenotype, taurine has generally been viewed as protective against cancer. Studies cited in the article show it can downregulate cyclins D1 and E and inhibit CDK4 and CDK6, blocking the G1-to-S transition and slowing tumor cell proliferation. Approximately 20 percent of the body’s taurine pool derives from the breakdown of taurine-conjugated bile acids, tying this amino acid intimately into bile acid metabolism.

Yet the picture is not so simple. The authors spotlight a 2024 Cell study identifying the taurine transporter SLC6A6 as a determinant of gastric cancer progression and recurrence. Tumor cells overexpress SLC6A6 and outcompete CD8-positive T cells for taurine, starving the immune cells and driving their exhaustion. Mechanistically, taurine depletion in T cells heightens endoplasmic reticulum stress, activating PERK-JAK1-STAT3 signaling and the transcription factor ATF4, which switches on multiple immune checkpoint genes. In gastric cancer, chemotherapy can upregulate the transcription factor SP1, further boosting SLC6A6 expression and intensifying this nutritional competition—a mechanism that may underlie both immune dysfunction and chemotherapy resistance. Taurine supplementation, the authors suggest, could serve as an adjunct therapy by protecting T cells and enhancing chemotherapy efficacy, but only in the right context.

That context-dependence is the commentary’s central message. Taurine’s function, like that of bile acids generally, is jointly determined by microenvironmental conditions, cell-type-specific metabolic capacity and host immune status—not by any single molecular property. This framing aligns with the integrative medicine philosophy articulated by Academician Daiming Fan, whose concepts of anti-cancer treatment, tumor control and life support emphasize restoring the body’s intrinsic regulatory forces rather than simply eliminating lesions. From this perspective, bile acid dysregulation is both a marker and a driver of the systemic imbalance that underlies cancer, and the liver-gut-immune axis becomes a concrete intervention point: modifying bile acid composition through diet, nutritional support or metabolic regulation may help rebuild an antitumor immune environment and ease treatment-related side effects.

The authors conclude that a multidimensional strategy centered on bile acid signaling offers a route from treating cancer as a local lesion toward managing it as a disorder of systemic homeostasis. By integrating molecular mechanisms with lifestyle and supportive therapies, and by individualizing approaches to taurine and bile acid pathways rather than applying blanket supplementation or inhibition, the framework points toward a more holistic, patient-centered integrative oncology—one in which the humble detergent molecules of digestion are recognized as key arbiters of life and disease.

Subject of Research: The roles of bile acids, their receptors and taurine metabolism in cancer biology and integrative oncology

Article Title: An integrative view of bile acids

Article References: Bai, X., Liu, B., Liu, L., Lu, Y., & Zhao, X. (2026). An integrative view of bile acids. Holistic Integrative Oncology, 5(1), Article 67. https://doi.org/10.1007/s44178-026-00290-9

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00290-9

Keywords: bile acids, FXR, TGR5, gut microbiota, taurine, SLC6A6, tumor microenvironment, colorectal cancer, obeticholic acid, integrative oncology, bile salt hydrolase, immune evasion